Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VISIONFLEX GROUP LIMITED Interim / Quarterly Report 2026

Feb 25, 2026

65999_rns_2026-02-25_9117117b-6e8b-4727-a289-b04e6c1979bd.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

ASX Announcement – 26 February 2026 Visionflex Group Limited (ASX:VFX)

==> picture [595 x 8] intentionally omitted <==

==> picture [155 x 23] intentionally omitted <==

H1 FY26 Financial Results

Highlights

  • H1 FY26 revenue of $1.7m, down 10% on the prior comparison period (pcp)

  • Recognised $0.9m in recurring revenue in H1 FY26, a 29% increase on pcp

  • Underlying EBITDA loss of $1.3m, consistent with the EBITDA loss in the pcp

  • Loss before tax of $0.1m after recognition of a $1.6m fair value gain from the conversion of convertible notes at a premium

  • $1.95m Annual Recurring Revenue (ARR) at 31 December 2025, up 23% on the pcp

  • $1.1m cash balance at 31 December 2025, with a further $1m of undrawn facilities available

  • A fundamentally stronger and more resilient balance sheet

Visionflex Group Limited (“ VFX ” or the “ Company ”), a leader in virtual healthcare solutions, is pleased to release its Appendix 4D and interim financial report for the 6 months ending 31 December 2025. A summary of the results released to market is outlined below.

Visionflex CEO & Managing Director, Joshua Mundey explained: “Our H1 FY26 results reflect the continued progress in repositioning Visionflex toward a higher-quality recurring revenue base. Our ARR increased 23% on the prior corresponding period to $1.95 million, with more than half of revenue generated from subscription and support services.

During the half, we maintained cost discipline, strengthened the balance sheet and progressed enterprise deployments, including partnerships with Amplar Health in delivering virtual nursing services into residential aged care and with Aspen Medical, supporting Aboriginal Community Controlled Health Organisations access primary care services. These initiatives demonstrate the scalability of our model where access and service delivery gaps remain a key issue in government linked settings.

While total revenue reflects the timing of enterprise contract execution and hardware delivery, the shift toward subscription based revenue provides a more stable platform for future performance. As further partnership initiatives scale and strategic integration pathways mature, we expect this momentum to support improved revenue performance in H2 FY26 and beyond.”

Financial Summary

The H1 FY26 financial summary is presented below:

==> picture [501 x 203] intentionally omitted <==

Visionflex Group Limited ACN 138 897 533 Unit 1, 8 Prosperity Parade, Warriewood NSW 2102

ASX Announcement – 26 February 2026 Visionflex Group Limited (ASX:VFX)

==> picture [595 x 8] intentionally omitted <==

==> picture [155 x 23] intentionally omitted <==

The H1 FY26 financial dashboard is presented below:

==> picture [503 x 224] intentionally omitted <==

A summary extract of the profit and loss statement for the continuing business is presented below:

==> picture [458 x 313] intentionally omitted <==

Revenue

Visionflex delivered H1 FY26 revenue of $1.7m, down 10% on the pcp, reflecting the timing of enterprise contract execution. Approximately 52% of revenue was generated from recurring software subscriptions and support (up from 36% in the pcp). The ARR contract portfolio increased to $1.95 million during the half, up 29% on the pcp.

Visionflex Group Limited ACN 138 897 533 Unit 1, 8 Prosperity Parade, Warriewood NSW 2102

ASX Announcement – 26 February 2026 Visionflex Group Limited (ASX:VFX)

==> picture [595 x 8] intentionally omitted <==

==> picture [155 x 23] intentionally omitted <==

Gross Margin

The gross profit margin increased to 85.4%, up from 80.8% in the pcp, reflecting a higher contribution from high margin subscription revenue. While revenue mix may vary between periods, the Company remains focused on improving margin quality through recurring revenue growth.

Expenses

Staff and operating costs remained broadly stable compared to H1 FY25, reflecting disciplined cost management and ongoing operational focus.

EBITDA

Visionflex delivered an Underlying EBITDA loss of $1.3m, broadly consistent with the pcp.

Cash and Cash Flow

As at 31 December 2025, the Company held cash and cash equivalents of $1.1m.

Customer cash receipts were $2.0m, up 25% on the pcp, reflecting improved collections and subscription growth.

Net cash used in operating activities was $1.3m, an improvement of $0.8m on the pcp, driven by a lower cash cost base and working capital discipline.

Debt

As at 31 December 2025, the Company had $1.0m available under its existing debt facility with cornerstone investor, Adcock Private Equity.

In February 2026, the availability period under the facility was extended to 28 February 2027.

Outlook

The Company remains focused on increasing recurring revenue through disciplined expansion across residential aged care, regional and remote health services, Indigenous health (including ACCHOs) and government linked programs.

Building on existing enterprise relationships, including Amplar Health, Aspen Medical and government linked organisations, Visionflex is pursuing multi-site deployments and expanded utilisation within its installed customer base.

Management continues to prioritise interoperability, clinical workflow integration and scalable deployment models to support sustainable growth.

Revenue timing in enterprise environments can vary between periods, however the Company expects improved performance in H2 FY26 as contracted deployments progress.

-- END --

This announcement was approved for release by the Board of Directors.

Visionflex Group Limited ACN 138 897 533 Unit 1, 8 Prosperity Parade, Warriewood NSW 2102

ASX Announcement – 26 February 2026 Visionflex Group Limited (ASX:VFX)

==> picture [595 x 8] intentionally omitted <==

==> picture [155 x 23] intentionally omitted <==

For more information:

Joshua Mundey Managing Director and CEO, Visionflex Group [email protected]

About Visionflex Group

At Visionflex, we believe that healthcare should be accessible, efficient, and connected. Our integrated hardware and software platform allows healthcare providers to deliver comprehensive, collaborative care in real time, no matter the location. From metropolitan health networks to community-based care, Visionflex is reshaping how healthcare is delivered by connecting healthcare teams with the tools and technology needed to provide effective, efficient, and high-quality care. For more information, visit vfx-group.com

Visionflex Group Limited ACN 138 897 533 Unit 1, 8 Prosperity Parade, Warriewood NSW 2102